Medium-term effects of beta-blockade on left ventricular mechanics: A double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction

Journal of Cardiac Failure

Volumn 2, Issue 1, 1996, Pages 15-23

  Rousseau, Michel F ^a   Chapelle, Frédéric ^a   Van Eyll, Christian ^a   Stoleru, Liviu ^a   Hager, David ^a   Van Nueten, Luc ^a   Pouleur, Hubert ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Atenolol; Ischemic left ventricular dysfunction; Nebivolol

Indexed keywords

ATENOLOL; BENZOPYRAN DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ETHANOLAMINE DERIVATIVE; NEBIVOLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ATENOLOL; BENZOPYRANS; DOUBLE-BLIND METHOD; ETHANOLAMINES; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 0030094440     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(96)80004-2     Document Type: Article

References (19)

1. Cruickshank JM: The β1-hyperselectivity in β-blocker treatment. J Cardiovasc Pharmaacol 1995;25(suppl I):S35-46
2. Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Progr Cardiovasc Dis 1985;28:335-71
3. Nemanich JW, Veith RC, Abrass IB, Stratton JR: Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. Am J Cardiol 1990;66:843-8
4. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, Bristow MR: β-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-41
5. Bristow MR, O'Conneli JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, One J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL, for the Bucindolol Investigators: Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-42
6. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP: Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994;23:943-50
7. Doughty RN, Mac Mahon S, Sharpe N: Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol 1994;23:814-21
8. Ikram H, Fitzpatrick D, Crozier IG: Therapeutic controversies with use of beta-adrenoceptor blockade in heart failure. Am J Cardiol 1993;71:54C-60C
9. Nuttall A, Snow HM: The cardiovascular effects of ICI 118,587: a β1-adrenoceptor partial agonist. Br J Pharmacol 1982;77:381-8
10. The German and Austrian Xamoterol Study Group: Double-blind placebo controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet 1988;i:489-93
11. The Xamoterol in Severe Heart Failure Study Group: Xamoterol in severe heart failure. Lancet 1990;336:1-6
12. Pouleur H, Rousseau MF, Oakley C, Rydén L, for the Xamoterol in Severe Heart Failure Study Group: Difference in mortality between patients treated with captopril or enalapril in the Xamoterol in Severe Heart Failure Study. Am J Cardiol 1991;68:71-4
13. DasGupta P, Broadhurst P, Raftery EB, Lahiri A: Value of carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:1118-23
14. Australia-New Zealand Heart Failure Research Collaborative Group: Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-8
15. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M: Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-506
16. Metra M, Nardi M, Giubbini R, Dei Cas L: Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-87
17. Van de Water A, Janssens W, Van Nueten JM, Xhonneux R, De Cré J, Verhaegen H, Reneman RS, Janssen PAJ: Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective β1-adrenergic antagonist. J Cardiovasc Pharmacol 1988;11:552-63
18. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P: Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094-100
19. Janssens WJ, Van de Water A, Xhonneux R, Reneman RS, Van Nueten JM, Janssen PAJ: Nebivolol is devoid of intrinsic sympathomimetic activity. Eur J Pharmacol 1989;159:89-95